Neurological disorders and the blood-brain barrier. Strategies and limitations for drug delivery to the brain;Afecciones neurológicas y barrera hematoencefálica. Limitaciones y estrategias para la liberación de fármacos al cerebro

Revista de Neurologia

Volumn 58, Issue 5, 2014, Pages 213-224

  Domínguez, Alazne ^a   Álvarez, Antonia ^b   Suárez Merino, Blanca ^a   Goñi de Cerio, Felipe ^a  

^a Centro Tecnologico Gaiker   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Blood brain barrier; Drug delivery systems; Endothelial cells; Neurological disorders; Permeability; Tight junctions

Indexed keywords

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; DRUG PENETRATION; GLIA CELL; NEUROLOGIC DISEASE; REVIEW; TIGHT JUNCTION; VASCULAR ENDOTHELIUM; ADULT; AGED; ASTROCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CYTOLOGY; ECONOMICS; ENDOTHELIUM CELL; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NERVE CELL; PERICYTE; PHYSIOLOGY; PREVALENCE; VERY ELDERLY;

CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIER;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTES; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURONS; PERICYTES; PREVALENCE;

EID: 84895477667     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5805.2013314     Document Type: Review

References (78)

1. Hyman S, Chisholm D, Kessler R, Patel V, Whiteford HA. Mental disorders in disease control priorities in developing countries. In Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, eds. Disease control priorities in developing countries. Washington DC: World Bank; 2006. p. 605-25.
2. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718-79.
3. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007; 6: 521-32.
4. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013; 36: 437-49.
5. DiNunzio JC, Williams RO. CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm 2008; 34: 1141-67.
6. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuro-psychopharmacol 2011; 21: 655-79.
7. Campenhausen SV, Bornschein B, Wick R, Tzel KB, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473-90.
8. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, López-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the Europarkinson Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.
9. Princea M, Brycea R, Emiliano Albanesea B, Anders Wimoc D, Wagner Ribeiroa E, Ferria CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75.
10. Vangilder RL, Rosen CL, Barr TL, Huber JD. Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther 2011; 130: 239-47.
11. Hung CW, Chen YC, Hsieh WL, Chiou SH, Kao CL. Ageing and neurodegenerative diseases. Ageing Res Rev 2010; 9: 36-46.
12. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007; 32: 1054-82.
13. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J 2012; 279: 1156-66.
14. Ayuso-Peralta L, De Andrés C. Tratamiento sintomático de la esclerosis múltiple. Rev Neurol 2002; 35: 1141-53.
15. Fernández O, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I). Rev Neurol 2013; 57: 217-29.
16. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64: 686-700.
17. Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol 2005; 12: 78-84.
18. Armstead WM, Ganguly K, Kiessling JW, Riley J, Chen XH, Smith DH, et al. Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of Tpa for treatment of CNS ischemic disorders. J Neurochem 2010; 113: 303-12.
19. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008; 113: 1953-68.
20. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
21. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155-62.
22. Nazem A, Mansoori GA. Nanotechnology for Alzheimer's disease detection and treatment. Insciences J 2011; 1: 169-93.
23. Bernacki J, Dobrowolska A, Nierwinska K, Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008; 60: 600-22.
24. Reichel A. Addressing central nervous system penetration in drug discovery: basics and implications of the evolving new concept. Chem Biodivers 2009; 6: 2030-49.
25. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54-61.
26. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Sci 2003; 6: 252-73.
27. Palmer AM. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol Dis 2009; 37: 3-12.
28. Lai CH, Kuo KH. The critical component to establish in vitro BBB model: pericyte. Brain Res Rev 2005; 50: 258-65.
29. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview. Structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13.
30. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
31. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005; 2: 54-62.
32. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98.
33. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 2004; 311: 449-55.
34. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
35. Pathan SA, Iqbal Z, Zaidi SM, Talegaonkar S, Vohra D, Jain GK, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009; 3: 71-89.
36. Rhim T, Lee DY, Lee M. Drug delivery systems for the treatment of ischemic stroke. Pharm Res 2013; 30: 2429-44.
37. Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 2011; 8: 581-603.
38. Garbayo E, Ansorena E, Blanco-Prieto MJ. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems. Maturitas 2013; S0378-5122: 182-5.
39. Nowacek A, Kosloski LM, Gendelman HE. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine 2009; 4: 541-55.
40. Rautioa J, Chikhale PJ. Drug delivery systems for brain tumor therapy. Curr Pharm Des 2004; 10: 1341-53.
41. Ross TM, Martínez PM, Renner JC, Thorne RG, Hanson LR, Frey WH. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004; 151: 66-77.
42. Vandergrift WA, Patel SJ, Nicholas JS, Varma AK. Convectionenhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus 2006; 20: E13.
43. Karanth H., Murthy Rayasa SR. Nanotechnology in brain targeting. IJPSN 2008; 1: 9-24.
44. Fortin D, Gendron C, Boudrias M, Garant, MP. Enhanced chemotherapy delivery by intraarterial infusion and bloodbrain barrier disruption in the treatment of cerebral metastasis. Cancer 2007; 109: 751-60.
45. Willis CL. Glia-induced reversible disruption of blood-brain barrier integrity and neuropathological response of the neurovascular unit. Toxicol Pathol 2011; 39: 172-85.
46. Johnson NJ, Hanson LR, Frey WH. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm 2010; 7: 884-93.
47. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9: S5.
48. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14.
49. Andrieux K, García-García E, Kim HR, Couvreur P. Colloidal carriers: a promising way to treat central nervous system diseases. J Nanoneurosci 2009; 1: 17-34.
50. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010; 6: 9-24.
51. Provenzale JM, Mohs AM. Nanotechnology in neurology-current status and future possibilities. US Neurology 2010; 6: 12-7.
52. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release 2007; 122: 324-30.
53. Ruiz MA, Clares B, Morales ME, Gallardo V. Vesicular lipidic systems, liposomes, PLO, and liposomes-PLO: characterization by electronic transmission microscopy. Drug Dev Ind Pharm 2008; 34: 1269-76.
54. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005; 2: 108-19.
55. Trapani A, De Giglio E, Cafagna D, Denora N, Agrimi G, Cassano T, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm 2011; 419: 296-307.
56. Chesselet MF, Carmichael ST. Animal models of neurological disorders. Neurotherapeutics 2012; 9: 241-4.
57. Hirsch EC. Animal models in neurodegenerative diseases. J Neural Transm Suppl 2007; 72: 87-90.
58. Manzano S, González J, Marcos A, Payno M, Villanueva C, Matías-Guiu J. Experimental models in Alzheimer's disease. Neurologia 2009; 24: 255-62.
59. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012: 845618.
60. Van der Star BJ, Vogel DY, Kipp M, Puentes F, Baker D, Amor S. In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets 2012; 11: 570-88.
61. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener 2011; 6: 11.
62. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006; 12: 5288-97.
63. Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen P, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol 2012; 14: 979-93.
64. Liebsch M, Grune B, Seiler A, Butzke D, Oelgeschläger M, Pirow R, et al. Alternatives to animal testing: current status and future perspectives. Arch Toxicol 2011; 85: 841-58.
65. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007; 6: 650-61.
66. Nicolazzo JA, Charman SA, Charman WN. Methods to assess drug permeability across the blood-brain barrier. J Pharm Pharmacol 2006; 58: 281-93.
67. Abbott NJ, Dolman DE, Drndarski S, Fredriksson SM. An improved in vitro blood-brain barrier model: rat brain endothelial cells co-cultured with astrocytes. Methods Mol Biol 2012; 814: 415-30.
68. Thanabalasundaram G, El-Gindi J, Lischper M, Galla HJ. Methods to assess pericyte-endothelial cell interactions in a coculture model. Methods Mol Biol 2011; 686: 379-99.
69. Culot M, Lundquist S, Vanuxeem D, Nion S, Landry C, Delplace Y, et al. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol In Vitro 2008; 22: 799-811.
70. Deli MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005; 25: 59-127.
71. Yuan W, Li G, Gil ES, Lowe TL, Fu BM. Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann Biomed Eng 2010; 38: 1463-72.
72. Brown RC, Morris AP, O'Neil RG. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007; 1130: 17-30.
73. Förster C, Silwedel C, Golenhofen N, Burek M, Kietz S, Mankertz J, et al. Occludin as direct target for glucocorticoidinduced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol 2005; 565: 475-86.
74. Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem 2008; 107: 1358-68.
75. Haseloff RF, Blasig IE, Bauer HC, Bauer H. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol 2005; 25: 25-39.
76. Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp 2011; 71: 113-28.
77. Ribeiro MM, Castanho MA, Serrano I. In vitro blood-brain barrier models-latest advances and therapeutic applications in a chronological perspective. Mini Rev Med Chem 2010; 10: 262-70.
78. Cucullo L, Marchi N, Hossain M, Janigro D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J Cereb Blood Flow Metab 2011; 31: 767-77.